PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the first patient has been treated in a Phase III clinical trial called CHAMPION PLATFORM to evaluate the safety and efficacy of cangrelor, a fast-acting, reversible intravenous (IV) antiplatelet agent for preventing platelet activation and aggregation during the clotting process.
